Vericiguat in heart failure with reduced ejection fraction: the right choice above all else? The answer may lie in time. Letter regarding the article 'Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy'

European Journal of Heart FailureEarly View Letter to the Editor Vericiguat in heart failure with reduced ejection fraction: the right choice above all else? The answer may lie in time. Letter regarding the article ‘Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy’ Sibo Wang, Sibo Wang orcid.org/0000-0002-3204-2710 Department of Cardiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, ChinaSearch for more papers by this authorQiushi Sun, Qiushi Sun Department of Geriatrics Cardiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China Department of Medicine, Physiology and Biophysics, UC Irvine Diabetes Center, University of California Irvine (UCI), Irvine, USASearch for more papers by this authorLiansheng Wang, Corresponding Author Liansheng Wang [email protected] orcid.org/0000-0001-8538-6560 Department of Cardiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China Corresponding author. Email: [email protected]Search for more papers by this author Sibo Wang, Sibo Wang orcid.org/0000-0002-3204-2710 Department of Cardiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, ChinaSearch for more papers by this authorQiushi Sun, Qiushi Sun Department of Geriatrics Cardiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China Department of Medicine, Physiology and Biophysics, UC Irvine Diabetes Center, University of California Irvine (UCI), Irvine, USASearch for more papers by this authorLiansheng Wang, Corresponding Author Liansheng Wang [email protected] orcid.org/0000-0001-8538-6560 Department of Cardiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China Corresponding author. Email: [email protected]Search for more papers by this author First published: 15 June 2023 https://doi.org/10.1002/ejhf.2931Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Pieske B, Pieske-Kraigher E, Lam CSP, Melenovský V, Sliwa K, Lopatin Y, et al.; VICTORIA Study Group. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy. Eur J Heart Fail. https://doi.org/10.1002/ejhf.2836 Published online ahead of print 30/03/23. 2Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al.; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020; 382: 1883–1893. https://doi.org/10.1056/NEJMoa1915928 3Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413–1424. https://doi.org/10.1056/NEJMoa2022190 4Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819–829. https://doi.org/10.1016/S0140-6736(20)31824-9 5Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al.; Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404–1413. https://doi.org/10.1093/eurheartj/ehs337 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation